RECRUITINGINTERVENTIONAL
Long-term, Substantial Weight Loss and Insulin Regulation of Lipolysis
About This Trial
It is not known how much improvement in insulin regulated lipolysis (the breakdown of triglycerides) occurs following substantial, sustained weight loss. Researchers will test the effects of inflammation and lipolysis regulation in people before and after bariatric surgery (sleeve gastrectomy) to answer these questions.
Who May Be Eligible (Plain English)
Who May Qualify:
- BMI 40 - 50 kg/m2.
- Mo active physical illness that would interfere with mobility or weight loss after bariatric surgery
Who Should NOT Join This Trial:
- Type 1 or Type 2 Diabetes diagnosis or fasting plasma glucose ≥126 mg/dL
- Active coronary artery disease
- Participation in structured exercise (\>2 times per week for 30 minutes or longer)
- Smoking
- Medications known to affect adipose tissue metabolism (e.g., beta blockers, corticosteroids)
- Renal insufficiency (serum creatinine \> 1.5mg/dl)
- Chronic active liver disease (Bilirubin \> 17mmol/L, AST \> 144 IU/L, or ALT\>165IU/L)
- Pregnancy or breastfeeding.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* BMI 40 - 50 kg/m2.
* Mo active physical illness that would interfere with mobility or weight loss after bariatric surgery
Exclusion Criteria:
* Type 1 or Type 2 Diabetes diagnosis or fasting plasma glucose ≥126 mg/dL
* Active coronary artery disease
* Participation in structured exercise (\>2 times per week for 30 minutes or longer)
* Smoking
* Medications known to affect adipose tissue metabolism (e.g., beta blockers, corticosteroids)
* Renal insufficiency (serum creatinine \> 1.5mg/dl)
* Chronic active liver disease (Bilirubin \> 17mmol/L, AST \> 144 IU/L, or ALT\>165IU/L)
* Pregnancy or breastfeeding.
Treatments Being Tested
PROCEDURE
Gastric sleeve/bariatric surgery
weight loss
Locations (1)
Mayo Clinic
Rochester, Minnesota, United States